Anna Szyndler

Anna Szyndler

Auto-generated profile, based on publicly available information

Anna Szyndler

Department of Hypertension and Diabetology, Medical University of Gdansk, Gdansk, Poland

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2016 in JACC: Basic To Translational Science
Verified
Journal Article
Open access
KNKrzysztof Narkiewicz
Krzysztof Narkiewicz
LRLaura E.K. Ratcliffe
Laura E.K. Ratcliffe
EHEmma C. Hart
Emma C. Hart
LBLinford J.B. Briant
Linford J.B. Briant
MCMarzena Chrostowska
Marzena Chrostowska
JPJulian F.R. Paton
Julian F.R. Paton
Animal and human data indicate pathological afferent signaling emanating from the carotid body that drives sympathetically mediated elevations in blood pressure in conditions of hypertension. This first-in-man, proof-of-principle study tested the safety and feasibility of unilateral carotid body resection in 15 patients with drug-resistant hypertension. The procedure proved to be safe and feasible. Overall, no change in blood pressure was found. However, 8 patients showed significant reductions in ambulatory blood pressure coinciding with decreases in sympathetic activity. The carotid body may be a novel target for treating an identifiable subpopulation of humans with hypertension.

1 April 2013 in Best Practice & Research Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
MCMarzena Chrostowska
Marzena Chrostowska
ASAnna Szyndler
Anna Szyndler
MHMichał Hoffmann
Michał Hoffmann
KNKrzysztof Narkiewicz
Krzysztof Narkiewicz

23 August 2019 in Polish Heart Journal
Verified
Journal Article
Closed access
APAleksander Prejbisz
Aleksander Prejbisz
PDPiotr Dobrowolski
Piotr Dobrowolski
PKPrzemysław Kosiński
Przemysław Kosiński
DBDorota Bomba-Opoń
Dorota Bomba-Opoń
MAMarcin Adamczak
Marcin Adamczak
AJAndrzej Januszewicz
Andrzej Januszewicz

1 November 2013 in Autonomic Neuroscience
Verified
Journal Article
Closed access
BGBeata Graff
Beata Graff
ASAnna Szyndler
Anna Szyndler
KCKrzysztof Czechowicz
Krzysztof Czechowicz
WKWiesława Kucharska
Wiesława Kucharska
GGGrzegorz Graff
Grzegorz Graff
KNKrzysztof Narkiewicz
Krzysztof Narkiewicz

21 August 2018 in Blood Pressure
Verified
Journal Article
Closed access
EŚEwa Świerblewska
Ewa Świerblewska
JWJacek Wolf
Jacek Wolf
KKKatarzyna Kunicka
Katarzyna Kunicka
BGBeata Graff
Beata Graff
KPKatarzyna Polonis
Katarzyna Polonis
KNKrzysztof Narkiewicz
Krzysztof Narkiewicz
Background: Although the presence of sub-clinical left ventricular diastolic dysfunction (LVDD) increases cardiovascular risk, the current ESH/ESC guidelines do not include the presence of this condition in the list of target organ damage or cardiovascular risk charts dedicated to the hypertensive population. Several conditions may predict the LVDD occurrence, however, clustering of these factors with hypertension makes the relationship less clear. Therefore, the aim of this study was to evaluate both the occurrence and the severity of diastolic dysfunction in a large cohort of treated hypertensives. Methods: We retrospectively analyzed records of 610 hypertensive participants of the CARE NORTH Study who consented to echocardiography and were free of overt cardiovascular disease. Mean age was 54.0 ± 13.9 years (mean ± SD), BMI 29.7 ± 4.8 kg/m2. The exclusion criteria were: established heart failure, LVEF <45%, coronary revascularization, valvular defect, atrial fibrillation, or stroke. The staging of LVDD was based on comprehensive transthoracic echocardiographic measurements. Results: 49.7% percent of the patients had normal diastolic function (38.8% vs. 59.0%, females (F) vs. males (M), respectively; p < .001). Grade 1 LVDD was documented in 24.4% (27.8% and 21.6%; F and M; p = .08) and grade 2 LVDD in 19.3% (24.9% and 14.6%; F and M; p = .001) of the patients. None were diagnosed with grade 3 LVDD. In the logistic regression model, female sex, advancing age, obesity status, established diabetes mellitus, higher 24-hour SBP, and increasing LVMI were identified as the independent variables increasing the odds for the presence of LVDD, whereas blood-lowering therapy attenuated the risk. Conclusions: There is an unexpectedly high prevalence of different forms of diastolic dysfunction in treated hypertensive patients who are free of overt cardiovascular disease.

14 March 2019 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
RWRenata Wawrzyniak
Renata Wawrzyniak
AMArlette Yumba Mpanga
Arlette Yumba Mpanga
WSWiktoria Struck-Lewicka
Wiktoria Struck-Lewicka
MKMarta Kordalewska
Marta Kordalewska
KPKatarzyna Polonis
Katarzyna Polonis
RBRenata Bujak
Renata Bujak
Background: Resistant hypertension (RH) affects about 15-20% of treated hypertensive patients worldwide. RH increases the risk of cardiovascular events such as myocardial infarction and stroke by 50%. The pathological mechanisms underlying resistance to treatment are still poorly understood. Objective: The main goal of this pilot study was to determine and compare plasma metabolomic profiles in resistant and non-resistant hypertensive patients. Methods: We applied untargeted metabolomic profiling in plasma samples collected from 69 subjects with RH and 81 subjects with controlled hypertension. To confirm patients’ compliance to antihypertensive treatment, levels of selected drugs and their metabolites were determined in plasma samples with the LC-ESI-TOF/MS technique. Results: The results showed no statistically significant differences in the administration of antihypertensive drug in the compared groups. We identified 19 up-regulated and 13 downregulated metabolites in the RH. Conclusion: The metabolites altered in RH are linked to oxidative stress and inflammation, endothelium dysfunction, vasoconstriction and cell proliferation. Our results may generate new hypothesis about RH development and progression.